ABVC BIOPHARMA, INC.

Nasdaq:ABVC

Pharmaceutical Preparations·FREMONT, CA

CEO

Crockett Robert G

CFO

Stolz Kevin Patrick

Financials

20 shown

Type	Period	Ended	Filed
10-K	FY 2025	12/31/25	3/3/26	→
10-Q/A	Q3 2025	9/30/25	3/3/26	→
10-Q	Q3 2025	9/30/25	11/3/25	→
10-Q	Q2 2025	6/30/25	8/13/25	→
10-Q	Q1 2025	3/31/25	4/30/25	→
10-K	FY 2024	12/31/24	4/15/25	→
↓

Earnings Releases (8-K)

13 shown

Filed	Period
3/3/26	Q1 FY2026	→
11/3/25	Q4 FY2025	→
8/14/25	Q3 FY2025	→
5/1/25	Q2 FY2025	→
4/16/25	Q1 FY2025AMENDMENT NO. 1 TO FORM 8-K	→
4/15/25	Q1 FY2025	→
↓

News (8-K)

67 shown

Filed	Type	Description
1/16/26	Other	AMENDMENT NO. 1 TO FORM 8-K	→
10/30/25	Exec Change	Departure or Appointment of Directors or Certain Officers	→
9/12/25	Other	AMENDMENT NO. 1 TO FORM 8-K	→
7/18/25	Agreement	AMENDMENT NO. 1 TO FORM 8-K	→
6/4/25	Vote	Submission of Matters to a Vote of Security Holders	→
5/30/25	Other	Unregistered Sales of Equity Securities	→
↓

Prospectuses & Registrations

40 shown

Filed	Form	Description
11/14/25	424B4	PROSPECTUS SUPPLEMENT	→
11/14/25	424B4	PROSPECTUS SUPPLEMENT	→
11/14/25	424B4	PROSPECTUS SUPPLEMENT	→
11/14/25	424B4	PROSPECTUS SUPPLEMENT	→
8/15/25	424B4	PROSPECTUS SUPPLEMENT	→
8/15/25	424B4	PROSPECTUS SUPPLEMENT	→
↓

Filing History(776 filings)

TypeDateAccessionPeriodSize

DEF 14A

Mar 5, 2026

0001213900-26-024122DEFINITIVE PROXY STATEMENT

Mar 26, 2026

495.6 KB

10-K

Mar 3, 2026

0001213900-26-023063ANNUAL REPORT

Dec 31, 2025

10.5 MB

10-Q/A

Mar 3, 2026

0001213900-26-023062AMENDMENT NO. 1 TO FORM 10-Q

Sep 30, 2025

11.2 MB

8-K

Mar 3, 2026

0001213900-26-023054CURRENT REPORT

Mar 3, 2026

239.5 KB

PRE 14A

Feb 5, 2026

0001213900-26-012888PRELIMINARY PROXY STATEMENT

Feb 5, 2026

489.7 KB

8-K/A

Jan 16, 2026

0001213900-26-005165AMENDMENT NO. 1 TO FORM 8-K

Apr 30, 2025

189.4 KB

424B4

Nov 14, 2025

0001213900-25-110903PROSPECTUS SUPPLEMENT

—

962.6 KB

424B4

Nov 14, 2025

0001213900-25-110902PROSPECTUS SUPPLEMENT

—

962.7 KB

424B4

Nov 14, 2025

0001213900-25-110900PROSPECTUS SUPPLEMENT

—

962.5 KB

424B4

Nov 14, 2025

0001213900-25-110898PROSPECTUS SUPPLEMENT

—

962.4 KB

8-K

Nov 3, 2025

0001213900-25-104900CURRENT REPORT

Nov 3, 2025

339.5 KB

10-Q

Nov 3, 2025

0001213900-25-104811QUARTERLY REPORT

Sep 30, 2025

9.9 MB

8-K

Oct 30, 2025

0001213900-25-103799CURRENT REPORT

Oct 28, 2025

185.4 KB

8-K/A

Sep 12, 2025

0001213900-25-086952AMENDMENT NO. 1 TO FORM 8-K

Oct 18, 2024

185.3 KB

424B4

Aug 15, 2025

0001213900-25-077489PROSPECTUS SUPPLEMENT

—

967.1 KB

424B4

Aug 15, 2025

0001213900-25-077487PROSPECTUS SUPPLEMENT

—

967.3 KB

424B4

Aug 15, 2025

0001213900-25-077482PROSPECTUS SUPPLEMENT

—

967.3 KB

424B4

Aug 15, 2025

0001213900-25-077476PROSPECTUS SUPPLEMENT

—

967.8 KB

424B4

Aug 15, 2025

0001213900-25-077473PROSPECTUS SUPPLEMENT

—

967.6 KB

8-K

Aug 14, 2025

0001213900-25-076018CURRENT REPORT

Aug 14, 2025

206.4 KB

SCHEDULE 13G/A

Aug 13, 2025

0000929638-25-003007

—

10.1 KB

10-Q

Aug 13, 2025

0001213900-25-075644QUARTERLY REPORT

Jun 30, 2025

9.6 MB

8-K/A

Jul 18, 2025

0001213900-25-065728AMENDMENT NO. 1 TO FORM 8-K

Feb 8, 2024

281.5 KB

SCHEDULE 13D/A

Jul 15, 2025

0001213900-25-064283

—

9.3 KB

S-8

Jun 27, 2025

0001213900-25-058995REGISTRATION STATEMENT

—

218.0 KB

25 filings shown

Filed	Form	Description
11/14/24	SC 13G/A	SC 13G/A	→
2/13/24	SC 13G/A	SC 13G/A	→
8/7/23	SC 13G	SC 13G	→
7/12/22	3	3	→
7/12/22	SC 13D	SCHEDULE 13D	→
3/31/22	3	3	→
↓

ABVC BIOPHARMA, INC.

Financials

Earnings Releases (8-K)

News (8-K)

Prospectuses & Registrations

Filing History(776 filings)

Proxies

Ownership

Other Filings

Filed	Form	Description
3/5/26	DEF 14A	DEFINITIVE PROXY STATEMENT	→
2/5/26	PRE 14A	PRELIMINARY PROXY STATEMENT	→
5/16/25	DEF 14A	DEFINITIVE PROXY STATEMENT	→
4/25/25	PRE 14A	PRELIMINARY PROXY STATEMENT	→
4/26/24	PRE 14A	PRELIMINARY PROXY STATEMENT	→
3/25/24	DEFA14A	DEFINITIVE ADDITIONAL MATERIALS	→
↓